Vamorolone

Alternative to existing steroids for Duchenne patients

The only current standard of care for boys with Duchenne is early treatment with long-term steroids, which gives some protection to muscles but with significant side effects. In July 2014, alongside three other Duchenne charities we funded a $2.1 million Phase 1 clinical trial of Vamorolone – an alternative anti-inflammatory drug that aims to maximise the benefit and minimise or remove side effects.

We were delighted to hear that in March 2016 the project received a further £4.6 million of funding from an EU grant known as Horizon 20/20, enabling the clinical trial to progress to Phase 2.

The charities contributed the funds under a co-ordinated venture philanthropy model, providing return on investment based on future drug sales. Vamorolone has been shown to be effective in animal models of Duchenne muscular dystrophy, and clinical trials in humans are now under way – in part, thanks to funds we and our partner charities have donated.

In June 2018 ReveraGen shared results from its international clinical trial in 48 boys aged 4-7, which showed dose-related improvements of multiple function tests of strength and endurance. Click here to read the press release.

What are the potential benefits?

In studies, the drug reduced inflammation and stabilised cell membranes, both of which are believed to be relevant to treating Duchenne, a disease in which muscle fibre membranes are unstable. The drug is thought to have similar properties to steroids such as prednisolone, which up until now have been the cornerstone of treatment for boys with Duchenne. The benefit of Vamorolone, however, is that it is thought to have significantly fewer side effects than existing steroids, which can be life changing in themselves. Side effects include diabetes, high blood pressure, osteoporosis, short stature and weight gain.

Pre-clinical research

£157,500 contribution

Funded in 2014

Maryland, USA

Learn more

Latest news about clinical trial capacity and other posts we fund

DRF funds Newcastle refurbishment

On Wednesday 27 September 2017, the newly refurbished paediatric area in the Clinical Research Facility at Newcastle Royal Victoria Infirmary was officially opened by Professor Mark Walker and Dr Michela Guglieri.

Ten posts in place to support UK clinical trial capacity

Today we are announcing that TEN posts have been filled out of sixteen clinical posts to support clinical trial development for Duchenne. The posts are part of a £1.2m investment by eight patient organisations under the Newcastle Plan.

Newcastle Plan aims to boost UK clinical trial capacity for Duchenne

Last month the Duchenne Research Fund participated in the UK National Workshop on Duchenne Muscular Dystrophy Clinical Trial Capacity at Newcastle University, hosted by TREAT-NMD. The landmark meeting brought together 75 representatives from patient organisations, pharmaceutical companies, the National Institute for Health Research and a wide range of clinicians, to discuss the challenges and solutions to increase clinical trial capacity in the UK …

Charities award fellowship to vital Duchenne researcher

The Duchenne Research Fund is part of a consortium of charities working on Duchenne muscular dystrophy that has awarded a Fellowship to Dr Michela Guglieri in partnership with Newcastle University and Newcastle University Teaching Hospital to develop and advance the clinical trial agenda for this devastating and currently incurable condition. The award of £250,000 over five years is being matched by Newcastle University …

The devastating impact of steroids

Click here to learn more about the effects that current steroid treatments have on boys with Duchenne.